SSelectStock

GKBGKB Ophthalmics Limited

Healthcare · Medical Instruments & Supplies · NSE · as of 2026-09-11 (delayed ~30 min in market hours)

GKB Ophthalmics Limited engages in the manufacture and sale of unfinished ophthalmic lenses in India and internationally. It offers semifinished organic lenses, such as single vision, bifocal, and progressive. The company was incorporated in 1981 and is based in Mapusa, India.

64.79
0.46%
44Weak

Mkt Cap
₹33 Cr
P/E
10.1
P/B
0.6
Div Yield
0.00%
52W High
₹88.40
52W Low
₹60.30

Price & Volume

Loading chart…

Key Ratios

Market Cap (₹ cr)32.70
P/E10.06
P/B0.60
PEG0.09
ROE %2.30
ROCE %8.40
Debt / Equity0.21
EPS6.44
Revenue Growth %2.30
Profit Growth %117.30
Dividend Yield %0.00
Promoter Holding %78.05
FII Holding %0.00
DII Holding %
Beta0.47

“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.

Active Pattern Signals

None of the 16 pattern scanners currently detects a setup on GKB — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.

AVOIDConviction 61%

Why avoid

  • Risk gate: safety score is only 25/100 — volatility, drawdown or liquidity is too poor for a buy call, whatever the chart says
  • Recently listed — limited trading history, scores are provisional
  • Revenue growth: 2.3% YoY
  • ROE: 2.3%
  • Insufficient price history

Bull case

  • Profit growth: 117.3% YoY
  • Debt/Equity: 0.21
  • Promoter holding: 78.0%
  • Volume trend: 2.2x baseline

Bear case

  • Recently listed — limited trading history, scores are provisional
  • Revenue growth: 2.3% YoY
  • ROE: 2.3%
  • Insufficient price history

Key risks

  • Elevated volatility / drawdown profile — size positions accordingly
  • Momentum is fading versus the broader market
  • Recently listed — limited trading history, scores are provisional
  • Revenue growth: 2.3% YoY

Algorithmic analysis for research only — not SEBI-registered investment advice.

Trade Plan

Entry (CMP)
₹64.79
Stop Loss
₹59.70
risk 7.9%
Target 1 (1.5R)
₹72.43
+11.8%
Target 2 (3R)
₹80.07
+23.6%
Support (20d)
₹60.30
Resistance (52w)
₹88.40
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹5.09/share
ATR (volatility)
₹3.35
avg daily range

Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹3.35). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.

Score Breakdown

Fundamental60
Technical50
Momentum29
Risk (safety)25

Peers — Healthcare

GKSL 1.23%
79
NEPHROPLUS 2.42%
74
KOVAI 1.41%
73
SAILIFE 0.38%
73
METROPOLIS 1.70%
73
VIJAYA 0.21%
72